Evidence map›Paper›PMID 40069775›Full record

ReviewMolecular cancer2025

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Yuxuan Wan, Guoqing Li, Gaoyuan Cui, Saili Duan, Shi Chang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuxuan WanDepartment of General Surgery, Xiangya Hospital Central South University, Changsha, 410008, Hunan, People's Republic of China.
Guoqing LiDepartment of General Surgery, Xiangya Hospital Central South University, Changsha, 410008, Hunan, People's Republic of China.
Gaoyuan CuiXiangya School of Medicine, Central South University, Changsha, 410008, Hunan, People's Republic of China.
Saili DuanDepartment of General Surgery, Xiangya Hospital Central South University, Changsha, 410008, Hunan, People's Republic of China. sailid@med.umich.edu.
Shi ChangDepartment of General Surgery, Xiangya Hospital Central South University, Changsha, 410008, Hunan, People's Republic of China. changshi@csu.edu.cn.

Funding

China Postdoctoral Science Foundation 2021T140749Fundamental Research Funds for the Central Universities of Central South University CX20210354National Natural Science Foundation of China 81902729Natural Science Foundation of Hunan Province 2020JJ4925Project Program of National Clinical Research Center for Geriatric Disorders 2021KFJJ03Special Funding for the Construction of Innovative Provinces in Hunan 2020SK4003
6 · The paper itself

Abstract

Thyroid cancer as one of the most prevalent malignancies of endocrine system, has raised public concern and more research on its mechanism and treatment. And metabolism-based therapies have advanced rapidly, for the exclusive metabolic profiling of thyroid cancer. In thyroid cancer cells, plenty of metabolic pathways are reprogrammed to accommodate tumor microenvironment. In this review, we initiatively summarize recent progress in the full-scale thyroid cancer metabolic rewiring and the interconnection of various metabolites. We also discuss the efficacy and prospect of metabolic targeted detection as well as therapy. Comprehending metabolic mechanism and characteristics of thyroid cancer roundly will be highly beneficial to managing individual patients.

Indexed as

Cellular ReprogrammingMetabolic Networks and PathwaysThyroid NeoplasmsAnimalsHumansMetabolomicsTumor MicroenvironmentCarcinogenesisDiagnosisGeneticsMetabolismTargeted therapyThyroid cancer

Identifiers

PMID40069775
PMCPMC11895238

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.